Skip to main content

Table 6 Summary of adverse events by treatment

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Preferred term

MET BID

RE BID

MET + RE BID

N = 13

N = 13

N = 13

n (%)

n (%)

n (%)

Any Event

5 (38%)

2 (15%)

7 (54%)

Headache

2 (15%)

0

1 (8%)

Back pain

2 (15%)

0

0

Muscle spasms

1 (8%)

1 (8%)

0

Hypoglycemia

1 (8%)

0

1 (8%)

Neck pain

1 (8%)

0

0

Osteoarthritis

0

0

1 (8%)

Abdominal pain upper

0

1 (8%)

0

Dyspepsia

0

0

1 (8%)

Toothache

1 (8%)

0

0

Dizziness

1 (8%)

0

0

Fatigue

1 (8%)

0

0

Nasopharyngitis

0

0

1 (8%)

Wound

0

0

1 (8%)

Rash

0

0

1 (8%)